These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21175581)

  • 21. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice.
    Zhang Y; Breevoort SR; Angdisen J; Fu M; Schmidt DR; Holmstrom SR; Kliewer SA; Mangelsdorf DJ; Schulman IG
    J Clin Invest; 2012 May; 122(5):1688-99. PubMed ID: 22484817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.
    Naik SU; Wang X; Da Silva JS; Jaye M; Macphee CH; Reilly MP; Billheimer JT; Rothblat GH; Rader DJ
    Circulation; 2006 Jan; 113(1):90-7. PubMed ID: 16365197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Squalene in a sex-dependent manner modulates atherosclerotic lesion which correlates with hepatic fat content in apoE-knockout male mice.
    Guillén N; Acín S; Navarro MA; Perona JS; Arbonés-Mainar JM; Arnal C; Sarría AJ; Surra JC; Carnicer R; Orman I; Segovia JC; Ruiz-Gutiérrez V; Osada J
    Atherosclerosis; 2008 Mar; 197(1):72-83. PubMed ID: 17854812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells.
    Nunomura S; Okayama Y; Matsumoto K; Hashimoto N; Endo-Umeda K; Terui T; Makishima M; Ra C
    Allergol Int; 2015 Sep; 64 Suppl():S11-7. PubMed ID: 26344074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.
    Leik CE; Carson NL; Hennan JK; Basso MD; Liu QY; Crandall DL; Nambi P
    Br J Pharmacol; 2007 Jun; 151(4):450-6. PubMed ID: 17420776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice.
    Duivenvoorden I; Voshol PJ; Rensen PC; van Duyvenvoorde W; Romijn JA; Emeis JJ; Havekes LM; Nieuwenhuizen WF
    Am J Clin Nutr; 2006 Aug; 84(2):312-21. PubMed ID: 16895877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages.
    Wang YY; Dahle MK; Steffensen KR; Reinholt FP; Collins JL; Thiemermann C; Aasen AO; Gustafsson JA; Wang JE
    Shock; 2009 Nov; 32(5):548-53. PubMed ID: 19295476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
    Skerrett R; Pellegrino MP; Casali BT; Taraboanta L; Landreth GE
    J Biol Chem; 2015 Aug; 290(35):21591-602. PubMed ID: 26163517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury.
    Lei P; Baysa A; Nebb HI; Valen G; Skomedal T; Osnes JB; Yang Z; Haugen F
    Basic Res Cardiol; 2013 Jan; 108(1):323. PubMed ID: 23266787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The LXR agonist GW3965 increases apoA-I protein levels in the central nervous system independent of ABCA1.
    Stukas S; May S; Wilkinson A; Chan J; Donkin J; Wellington CL
    Biochim Biophys Acta; 2012 Mar; 1821(3):536-46. PubMed ID: 21889608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists.
    Koura M; Matsuda T; Okuda A; Watanabe Y; Yamaguchi Y; Kurobuchi S; Matsumoto Y; Shibuya K
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2668-74. PubMed ID: 25998501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.
    Wang Y; Parlevliet ET; Geerling JJ; van der Tuin SJ; Zhang H; Bieghs V; Jawad AH; Shiri-Sverdlov R; Bot I; de Jager SC; Havekes LM; Romijn JA; Willems van Dijk K; Rensen PC
    Br J Pharmacol; 2014 Feb; 171(3):723-34. PubMed ID: 24490861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.
    Kühnast S; Louwe MC; Heemskerk MM; Pieterman EJ; van Klinken JB; van den Berg SA; Smit JW; Havekes LM; Rensen PC; van der Hoorn JW; Princen HM; Jukema JW
    PLoS One; 2013; 8(6):e66467. PubMed ID: 23840481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice.
    Archer A; Venteclef N; Mode A; Pedrelli M; Gabbi C; Clément K; Parini P; Gustafsson JÅ; Korach-André M
    Mol Endocrinol; 2012 Dec; 26(12):1980-90. PubMed ID: 23073827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice.
    Teupser D; Kretzschmar D; Tennert C; Burkhardt R; Wilfert W; Fengler D; Naumann R; Sippel AE; Thiery J
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2009-15. PubMed ID: 18787185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα.
    Kiss E; Popovic Z; Bedke J; Wang S; Bonrouhi M; Gretz N; Stettner P; Teupser D; Thiery J; Porubsky S; Adams J; Gröne HJ
    Am J Pathol; 2011 Jul; 179(1):92-103. PubMed ID: 21703396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates.
    Kirchgessner TG; Martin R; Sleph P; Grimm D; Liu X; Lupisella J; Smalley J; Narayanan R; Xie Y; Ostrowski J; Cantor GH; Mohan R; Kick E
    J Pharmacol Exp Ther; 2015 Feb; 352(2):305-14. PubMed ID: 25467132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels.
    Brunham LR; Kruit JK; Pape TD; Parks JS; Kuipers F; Hayden MR
    Circ Res; 2006 Sep; 99(7):672-4. PubMed ID: 16946132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice.
    Grefhorst A; van Dijk TH; Hammer A; van der Sluijs FH; Havinga R; Havekes LM; Romijn JA; Groot PH; Reijngoud DJ; Kuipers F
    Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E829-38. PubMed ID: 15941783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.